Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
Open Access
- 16 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 124 (6), 1072-1078
- https://doi.org/10.1038/s41416-020-01208-6
Abstract
Background Patients with refractory colorectal (CRC) cancer have few treatment options. This trial tests the combination of metformin and irinotecan in this setting. Methods A phase 2 single-arm trial was conducted, patients received metformin 2500 mg orally a day plus irinotecan 125 mg/m(2) intravenously weekly D1 and D8 every 21 days. The primary endpoint was the disease control rate according to the Response Evaluation Criteria in Solid Tumors version 1.1 at 12 weeks. Results Between December 2015 and January 2018, 41 patients were enrolled. Seventeen patients (41%) met the primary endpoint of disease control in 12 weeks; hence, the study was deemed positive. The median progression-free survival was 3.3 months (CI 95%, 2.0-4.5 months), and the median overall survival was 8.4 months (CI 95%, 5.9-10.8 months). Both mutation RAS status and disease control at 12 weeks impacted overall survival in the multivariate model (HR 2.28, CI 95%, 1.12-4.7, p = 0.02; and HR 0.21, CI 95%, 0.08-0.5, p = 0.001, respectively). The most common adverse event was diarrhoea (29.2% grade 3). Conclusions In this trial, metformin plus irinotecan demonstrated disease control in patients with refractory CRC. Further trials with optimised diarrhoea control are needed to confirm these results.This publication has 31 references indexed in Scilit:
- Metformin in Cancer Treatment and PreventionAnnual Review of Medicine, 2015
- Survival Benefits of Metformin for Colorectal Cancer Patients with Diabetes: A Systematic Review and Meta-AnalysisPLOS ONE, 2014
- Platinum-sensitivity in metastatic colorectal cancer: Towards a definitionEuropean Journal of Cancer, 2013
- Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to TherapyMolecular Cancer Therapeutics, 2013
- Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancerJournal of Experimental & Clinical Cancer Research, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral GrowthClinical Cancer Research, 2011
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989